APA (7th ed.) Citation

Thallinger, C., Lang, I., Kuhar, C. G., Bartsch, R., Singer, C. F., Petruzelka, L., . . . Zielinski, C. (2016). Phase II study on the efficacy and safety of Lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu- positive advanced breast cancer: Results of the CECOG LaVie trial. BMC Cancer, 16, 121. https://doi.org/10.1186/s12885-016-2171-y

Chicago Style (17th ed.) Citation

Thallinger, Christiane, et al. "Phase II Study on the Efficacy and Safety of Lapatinib Administered Beyond Disease Progression and Combined with Vinorelbine in HER-2/neu- Positive Advanced Breast Cancer: Results of the CECOG LaVie Trial." BMC Cancer 16 (2016): 121. https://doi.org/10.1186/s12885-016-2171-y.

MLA (9th ed.) Citation

Thallinger, Christiane, et al. "Phase II Study on the Efficacy and Safety of Lapatinib Administered Beyond Disease Progression and Combined with Vinorelbine in HER-2/neu- Positive Advanced Breast Cancer: Results of the CECOG LaVie Trial." BMC Cancer, vol. 16, 2016, p. 121, https://doi.org/10.1186/s12885-016-2171-y.